Rookie network adds veteran CEO

Share this article:

Two-year-old health network Good Health Advertising (GHA) tapped Bill Jennings, an interactive sales expert, as its new CEO.


Jennings, a 20-year veteran of interactive sales and marketing teams at companies such as A&E and News Corp, said the GHA network is focused on three areas: condition-specific consumer health sites (familydoctor.org, spinehealth.com), a consumer wellness channel and healthcare professional sites (practicefusion.com).


"We have a technology to anonymously identify the heaviest users of a particular condition site and the ability to re-target users across the web," said Jennings of GHA. "For example, we can identify people that have visited a diabetes site or section of a site three or more times in the past 30 days, and group them as part of a diabetes audience. Ads can then be targeted to this group on GHA partner sites and on many other general sites outside of our network."


GHA's pharmaceutical clients include Schering-Plough, GlaxoSmithKline, Wyeth, Novartis, Merck, Pfizer and Genentech.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.